SCHEMBL9944340

SCHEMBL9944340

CCOc1c(Cl)cc(C(=O)Nc2ccc(C=O)c(C)c2)cc1OC1CCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
TP53 P04637 2/20 0.44
RORC P51449 1/20 0.41
PDE5A O76074 1/20 0.41
PDE1A P54750 1/20 0.41
PDE1B Q01064 1/20 0.41
PDE1C Q14123 1/20 0.41
GAA P10253 2/20 0.40
ALDH1A1 P00352 4/20 0.40
HPGD P15428 3/20 0.40
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
ABL1 P00519 1/20 0.40
RIN1 Q13671 1/20 0.40
PDE4A P27815 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9944316 0.90 PDE5A (0.47) MAPTMEN1KMT2ARORCPDE5A
SCHEMBL9944233 0.88 MAPT (0.50) MAPTNPSR1MEN1KMT2ARAB9A
SCHEMBL9944323 0.88 TAS1R3 (0.44) MAPTMEN1KMT2ARAB9ANPC1
SCHEMBL1457736 0.87 RAB9A (0.51) MAPTNPSR1MEN1KMT2ARAB9A
SCHEMBL9944354 0.87 MAPT (0.49) MAPTNPSR1MEN1KMT2ARAB9A
SCHEMBL9944319 0.87 MAPT (0.48) MAPTNPSR1MEN1KMT2ARAB9A
SCHEMBL9944303 0.87 MEN1 (0.51) MAPTNPSR1MEN1KMT2ARAB9A
SCHEMBL9944331 0.85 RAB9A (0.49) MAPTNPSR1MEN1KMT2ARAB9A
SCHEMBL1458518 0.84 MEN1 (0.55) MAPTNPSR1MEN1KMT2ARAB9A
SCHEMBL9944223 0.84 MAPT (0.48) MAPTNPSR1MEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG MAPT 150/4885NPSR1 826/4885MEN1 4809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.